Osang Healthcare Co.,Ltd (KOSDAQ:036220)
12,190
-310 (-2.48%)
Dec 10, 2025, 3:30 PM KST
Osang Healthcare Co.,Ltd Revenue
Osang Healthcare Co.,Ltd had revenue of 25.49B KRW in the quarter ending September 30, 2025, with 24.77% growth. This brings the company's revenue in the last twelve months to 119.03B, up 57.22% year-over-year. In the year 2024, Osang Healthcare Co.,Ltd had annual revenue of 80.49B, down -77.38%.
Revenue (ttm)
119.03B
Revenue Growth
+57.22%
P/S Ratio
1.44
Revenue / Employee
358.53M
Employees
332
Market Cap
171.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80.49B | -275.36B | -77.38% |
| Dec 31, 2023 | 355.85B | 161.95B | 83.53% |
| Dec 31, 2022 | 193.89B | 61.57B | 46.53% |
| Dec 31, 2021 | 132.33B | -125.64B | -48.70% |
| Dec 31, 2020 | 257.97B | 207.58B | 412.01% |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |